JPX · 4572.T
Carna Biosciences, Inc.
¥363-¥6 (-1.63%)
Carna Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 29.1% below the high.
Loading market information…
JPX · 206A.T · JPY
Stock price, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
PRISM BioLab Co.,LTD’s quoted price sits in the lower half of its reported 52-week range, 52.69% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
PRISM BioLab Co.,LTD’s next earnings report is currently expected on Nov 13, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow PRISM BioLab Co.,LTD’s reporting calendar.
THE COMPANY BEHIND THE TICKER
PRISM BioLab Co., LTD. engages in the research and development of pharmaceuticals using its proprietary drug discovery platform, PepMetics Technology. The company's technology focuses on creating peptide mimetic small molecules designed to mimic α-helix or β-turn peptides, which are essential for protein-protein interactions. Through its platform, PRISM aims to discover drugs for what were previously considered 'undruggable targets,' with a pipeline including candidates for cancer and fibrotic diseases.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:07 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥363-¥6 (-1.63%)
Carna Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 29.1% below the high.
¥135-¥1 (-0.74%)
TMS Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 18.18% below the high.
¥559-¥5 (-0.89%)
Cyfuse Biomedical K.K.’s quoted price sits in the lower half of its reported 52-week range, 26.83% below the high.
¥40-¥1 (-2.44%)
BrightPath Biotherapeutics Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 58.33% below the high.
¥212-¥2 (-0.93%)
Soiken Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.77% below the high.
¥85-¥2 (-2.3%)
Noile-Immune Biotech Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.83% below the high.
¥64-¥2 (-3.03%)
Ribomic Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.67% below the high.
¥59-¥2 (-3.28%)
D. Western Therapeutics Institute, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.85% below the high.
